The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: 0.100 @ >1:102,400
ICC/IF: 1+ @ 1:6,400
WB: Use at an assay dependent dilution. PubMed 16571817.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceThere are 2 antigenic types of Herpes Simplex Virus, HSV1 and HSV2 which share antigenic cross reactivity but different neutralization patterns and tend to produce different clinical symptoms. Humans are believed to be the natural host for HSV, but the virus is also capable of infecting various animals, including rodents.
Envelope glycoprotein E antibody
Glycoprotein E antibody
Human Herpesvirus 1 antibody
References for Anti-HSV1 gE Envelope Protein antibody [9H3] (ab6510)
This product has been referenced in:
Oda S et al. The Interaction between Herpes Simplex Virus 1 Tegument Proteins UL51 and UL14 and Its Role in Virion Morphogenesis. J Virol90:8754-67 (2016).
Read more (PubMed: 27440890) »
Maringer K et al. A network of protein interactions around the herpes simplex virus tegument protein VP22. J Virol86:12971-82 (2012).
Read more (PubMed: 22993164) »